Jason Butler Analyst PerformanceManaging Director at Citizens JmpJason Butler is a stock analyst at Citizens Jmp focused in the healthcare sector, covering 30 publicly traded companies. Over the past year, Jason Butler has issued 45 stock ratings, including buy and hold recommendations. While full access to Jason Butler's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Butler's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings129 Last 11 YearsBuy Recommendations91.94% 114 Buy RatingsCompanies Covered30 Unique Companies Ratings Distribution124RatingsDistribution of strong buy, buy, hold, and sell ratings by Jason Butler.RatingPercentageCount Strong Buy0.8%1 ratings Buy91.1%113 ratings Hold8.1%10 ratings Sell0.0%0 ratingsOut of 124 total stock ratings issued by Jason Butler at Citizens Jmp, the majority (91.1%) have been Buy recommendations, followed by 8.1% Hold and 0.8% Strong Buy.Best & Worst CallsBest Call000000.0%ABVXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ESPRJun 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ90.0% of companies on NASDAQ27 companiesNYSEAMERICAN6.7% of companies on NYSEAMERICAN2 companiesOTCMKTS3.3% of companies on OTCMKTS1 companyJason Butler, an analyst at Citizens Jmp, currently covers 30 companies listed on NASDAQ, NYSEAMERICAN and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare28 companies93.3%Technology1 company3.3%Communication Services1 company3.3%Jason Butler of Citizens Jmp specializes in stock coverage within the Healthcare sector, with additional focus on Technology and Communication Services companies.Coverage IndustriesIndustryPercentagePHARMACEUTICALS15 companies50.0%BIOTECHNOLOGY13 companies43.3%SOFTWARE1 company3.3%MEDIA1 company3.3% About Jason ButlerDr. Jason N. Butler is a Managing Director at Citizens JMP Securities LLC. He is covering the biotechnology industry. Prior to joining JMP Securities, he served as a Senior Associate Equity Analyst at Rodman & Renshaw covering biotechnology companies focused on therapies for metabolic and infectious diseases. Dr. Butler received his Bachelor’s degree in Biology and a PhD in Neuroscience from Imperial College London.Follow on LinkedIn Jason Butler's Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsARGXargenex8/18/2026Boost Price Target$987.84$1,200.00Market Outperform$0.0000.00% ROILONAAthira Pharma8/17/2026Lower Price Target$7.98$17.00Market Outperform$0.0000.00% ROICYTKCytokinetics8/7/2026Boost Price Target$76.26$110.00Market Outperform$0.0000.00% ROIHALOHalozyme Therapeutics8/7/2026Boost Price Target$98.86$93.00Market Outperform$0.0000.00% ROIZVRAZevra Therapeutics8/6/2026Boost Price Target$10.53$28.00Market Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals8/5/2026Boost Price Target$28.66$36.00Market Outperform$0.0000.00% ROILONAAthira Pharma7/30/2026Upgrade$7.04$18.00Outperform$0.0000.00% ROIARGXargenex7/24/2026Lower Price Target$924.60$932.00Market Outperform$0.0000.00% ROIABVXAbivax7/1/2026Reiterated Rating$135.99$187.00Market Outperform$0.0000.00% ROIZVRAZevra Therapeutics6/9/2026Boost Price Target$13.05$25.00Market Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RZLTRezolute6/3/2026Upgrade$4.00$11.00Outperform$0.0000.00% ROIABVXAbivax6/2/2026Boost Price Target$129.69$187.00Market Outperform$0.0000.00% ROIABVXAbivax5/26/2026Reiterated Rating$121.99$131.00Market Outperform$0.0000.00% ROIGHRSGH Research5/15/2026Lower Price Target$22.21$39.00Market Outperform$0.0000.00% ROIPGENPrecigen5/14/2026Boost Price Target$4.65$11.00Market Outperform$0.0000.00% ROIAVTXAvalo Therapeutics5/14/2026Lower Price Target$19.59$55.00Market Outperform$0.0000.00% ROIPRTAProthena5/8/2026Boost Price Target$10.85$20.00Market Outperform$0.0000.00% ROIAVTXAvalo Therapeutics5/6/2026Boost Price Target$21.87$62.00Market Outperform$0.0000.00% ROIESPREsperion Therapeutics5/1/2026Downgrade$3.12Hold$0.0000.00% ROICRMDCorMedix4/28/2026Reiterated Rating$7.64$19.00Market Outperform$0.0000.00% ROINERVMinerva Neurosciences4/15/2026Initiated Coverage$5.87$14.00Market Outperform$0.0000.00% ROIAVTXAvalo Therapeutics4/6/2026Initiated Coverage$17.76$52.00Outperform$0.0000.00% ROIPGENPrecigen3/26/2026Boost Price Target$4.04$9.00Market Outperform$0.0000.00% ROINSRXNasus Pharma3/26/2026Lower Price Target$2.66$18.00Market Outperform$0.0000.00% ROIESPREsperion Therapeutics3/13/2026Boost Price Target$2.47$5.00Market Outperform$0.0000.00% ROIGHRSGH Research3/6/2026Boost Price Target$15.17$42.00Market Outperform$0.0000.00% ROIARGXargenex2/27/2026Boost Price Target$771.53$944.00Market Outperform$0.0000.00% ROIIRWDIronwood Pharmaceuticals2/26/2026Boost Price Target$3.67$10.00Market Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/26/2026Boost Price Target$23.80$35.00Market Outperform$0.0000.00% ROICYTKCytokinetics2/25/2026Boost Price Target$70.10$96.00Market Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/3/2026Reiterated Rating$26.13$34.00Market Outperform$0.0000.00% ROIIRWDIronwood Pharmaceuticals1/5/2026Upgrade$4.27$8.00Market Outperform$0.0000.00% ROICYTKCytokinetics12/22/2025Boost Price Target$62.72$88.00Market Outperform$0.0000.00% ROIABVXAbivax12/16/2025Boost Price Target$117.91$131.00Market Outperform$0.0000.00% ROIRZLTRezolute12/11/2025Downgrade$1.80Hold$0.0000.00% ROIPRTAProthena12/1/2025Set Price Target$10.75$19.00$0.0000.00% ROIPRTAProthena12/1/2025Boost Price Target$10.75$19.00Market Outperform$0.0000.00% ROIACHVAchieve Life Sciences11/25/2025Initiated Coverage$3.97$19.00Market Outperform$0.0000.00% ROIRAPPRapport Therapeutics11/7/2025Boost Price Target$25.12$80.00Market Outperform$0.0000.00% ROIHALOHalozyme Therapeutics11/4/2025Boost Price Target$66.20$92.00Market Outperform$0.0000.00% ROIRickards Predicts: Trump to buy tiny $2 stock? (Ad)Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.Click here to see why Rickards believes this stock is nextWULFTeraWulf10/29/2025Boost Price Target$15.55$22.00Market Outperform$0.0000.00% ROIRZLTRezolute10/29/2025Boost Price Target$9.54$17.00Market Outperform$0.0000.00% ROIAQSTAquestive Therapeutics10/9/2025Boost Price Target$6.20$12.00Market Outperform$0.0000.00% ROIABVXAbivax9/25/2025Boost Price Target$82.55$114.00Market Outperform$0.0000.00% ROICRMDCorMedix9/9/2025Reiterated Rating$12.75$22.00Market Outperform$0.0000.00% ROIPRTAProthena9/2/2025Lower Price Target$8.20$11.00Market Outperform$0.0000.00% ROICYTKCytokinetics9/2/2025Reiterated Rating$47.43$78.00Market Outperform$00.0000.00% ROIPGENPrecigen8/19/2025Boost Price Target$2.95$8.00Market Outperform$0.0000.00% ROIZVRAZevra Therapeutics8/13/2025Lower Price Target$9.25$18.00Market Outperform$00.0000.00% ROIACADACADIA Pharmaceuticals8/7/2025Boost Price Target$23.80$38.00Market Outperform$00.0000.00% ROIHALOHalozyme Therapeutics8/6/2025Boost Price Target$64.95$91.00Market Outperform$00.0000.00% ROIABVXAbivax7/23/2025Boost Price Target$10.00$95.00Market Outperform$000.0000.00% ROIABVXAbivax7/18/2025Set Price Target$10.34$33.00$000.0000.00% ROIRAPPRapport Therapeutics7/8/2025Reiterated Rating$12.42$28.00Market Outperform$00.0000.00% ROIACADACADIA Pharmaceuticals6/26/2025Reiterated Rating$22.51$37.00Market Outperform$00.0000.00% ROIGHRSGH Research6/24/2025Reiterated Rating$11.86$39.00Market Outperform$00.0000.00% ROIPGENPrecigen6/12/2025Reiterated Rating$1.52$6.00Market Outperform$0.0000.00% ROIPRTAProthena5/27/2025Lower Price Target$6.58$29.00Market Outperform$00.0000.00% ROIARGXargenex5/14/2025Set Price Target$533.88$699.00$000.0000.00% ROITTDTrade Desk5/9/2025Lower Price Target$72.98$100.00Market Outperform$00.0000.00% ROIPRTAProthena5/9/2025Lower Price Target$7.85$78.00Market Outperform$00.0000.00% ROIVRDNViridian Therapeutics5/7/2025Lower Price Target$12.29$38.00Market Outperform$00.0000.00% ROIABVXAbivax4/30/2025Reiterated Rating$7.32$33.00Market Outperform$000.0000.00% ROIIRWDIronwood Pharmaceuticals4/14/2025Downgrade$0.65Market Perform$0.0000.00% ROICYTKCytokinetics4/10/2025Reiterated Rating$35.74$78.00Market Outperform$00.0000.00% ROIRAPPRapport Therapeutics4/8/2025Initiated Coverage$8.93$28.00Market Outperform$00.0000.00% ROIZVRAZevra Therapeutics3/12/2025Set Price Target$8.27$18.00$00.0000.00% ROIRZLTRezolute2/13/2025Boost Price Target$4.92$9.00Market Outperform$0.0000.00% ROICYTKCytokinetics2/7/2025Reiterated Rating$43.66$78.00Market Outperform$00.0000.00% ROIARGXargenex1/14/2025Boost Price Target$670.40$696.00Market Outperform$000.0000.00% ROICYTKCytokinetics1/14/2025Reiterated Rating$46.71$78.00Market Outperform$00.0000.00% ROIPGENPrecigen1/14/2025Reiterated Rating$1.14$5.00Market Outperform$0.0000.00% ROIABVXAbivax12/4/2024Upgrade$8.89Strong-Buy$000.0000.00% ROISYRSSyros Pharmaceuticals11/13/2024Reiterated Rating$2.73Market Perform$0.0000.00% ROIZVRAZevra Therapeutics9/24/2024Initiated Coverage$7.58$17.00Outperform$0.0000.00% ROILONAAthira Pharma9/4/2024Downgrade$2.83Market Perform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
